A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome

  title={A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome},
  author={Rajesh C. Sachdeo and Terry Ann Glauser and Frank J. Ritter and R A Reife and Pilar C. Lim and Gordon W. Pledger},
  pages={1882 - 1882}
Objective: To evaluate the efficacy and safety of topiramate as adjunctive therapy for Lennox–Gastaut syndrome in a multicenter, double-blind, placebo-controlled trial. Background: Conventional antiepileptic drugs are frequently ineffective against multiple-seizure types of Lennox–Gastaut syndrome. Methods: Ninety-eight patients >1 year to <30 years of age, with slow spike-and-wave patterns on EEG, seizure types including drop attacks, and either a history of or active atypical absence seizures… Expand
Rufinamide as an adjunctive therapy for Lennox–Gastaut syndrome: A randomized double-blind placebo-controlled trial in Japan
The present results showed a favorable risk-benefit profile for rufinamide as an adjunctive therapy for patients with LGS and subgroup analyses indicated that the efficacy of ruf inamide was consistent independent of clinical background characteristics. Expand
Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome
Rufinamide was an effective and well-tolerated treatment for seizures associated with Lennox–Gastaut syndrome and had a greater improvement in seizure severity than placebo. Expand
Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome
This study provides Class II evidence that clobazam as adjunctive therapy is efficacious, in a dosage-dependent manner, in reducing mean weekly drop seizure rates of patients with LGS over 12 weeks. Expand
Rufinamide for the treatment of Lennox–Gastaut syndrome
  • F. Besag
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2011
The data support a role for rufinamide in treating Lennox–Gastaut syndrome, but more efforts are required to provide antiepileptic drugs for this treatment-resistant epilepsy syndrome. Expand
A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy
Evidence is provided that topiramate is effective as monotherapy in patients with localization-related epilepsy with between-group differences in seizure-free rates, and longer time-to-first-seizure with higher serum concentration. Expand
An open label trial of topiramate as add-on therapy for Malaysian children with inadequately controlled epilepsy
Topiramate appears to be efficacious and safe in children with a wide variety of refractory seizures and in patients with poor seizure control and concomitant adverse events. Expand
Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome
Rufinamide appears to be a safe and effective adjuvant treatment for many cases of intractable LGS and should be considered as an add-on treatment in children and adolescents with Lennox-Gastaut syndrome. Expand
Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial
TPM may be a useful drug in patients with SMEI, being particularly effective against generalized tonic-clonic seizures, according to seizure type and frequency. Expand
Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome.
Rufinamide is more effective, but more expensive, than alternative adjunctive therapies approved for use in patients with LGS in the UK, and would appear to be a cost-effective alternative to topiramate. Expand
Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy)
Rufinamide produced statistically significant seizure reduction which was maintained during long-term therapy and accompanied by good tolerability and is a promising candidate for the adjunctive therapy of Lennox-Gastaut syndrome. Expand


Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy
Results of this trial strongly suggest that topiramate 400 mg/day is effective and well tolerated in the treatment of refractory partial epilepsy. Expand
Double‐Blind, Placebo‐Controlled Trial of Topiramate as Add‐on Therapy in Patients with Refractory Partial Seizures
The present study further establishes the favorable profile and good benefithisk ratio of TPM in resistant partial epilepsy and confirms its use in patients with refractory partial epilepsy. Expand
Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.
Lamotrigine was an effective and well-tolerated treatment for seizures associated with the Lennox-Gastaut syndrome and there were no significant differences in the incidence of adverse events. Expand
Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).
Felbamate is beneficial in patients with the Lennox-Gastaut syndrome and there was a significant reduction in the number of tonic-clonic seizures during the maintenance period in the felbamate group. Expand
Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages
Topiramate is a highly efficacious and generally well tolerated new AED and incremental efficacy in the add-on setting is not observed at topiramate dosages above 600 mg/day; however, higher doses may prove beneficial to individual patients who tolerate them. Expand
Topiramate: a review of preclinical, pharmacokinetic, and clinical data.
The efficacy of topiramate 200 to 1000 mg/d administered in two divided doses as adjunctive therapy for partial-onset seizures was investigated in five double-masked, placebo-controlled trials and most patients who experienced adverse events during the first 8 weeks of the trials no longer experienced them by their last visit. Expand
Double‐Blind, Placebo‐Controlled Trial of Topiramate (600 mg Daily) for the Treatment of Refractory Partial Epilepsy
Evaluating adjunctive therapy for partial‐onset seizures with topiramate with efficacy and safety in a double‐blind, placebo‐controlled, randomized, parallel‐group study found TPM to be safe and effective. Expand
New antiepileptic drugs.
The present review of newer antiepileptic drugs released in the United States consists of a brief summary of background information on each drug, followed by a closer analysis of recently published papers. Expand
Aplastic Anemia in a Patient Receiving Felbamate for Complex Partial Seizures
The association between fel bamate and aplastic anemia has resulted in a joint recommendation by the US Food and Drug Administration and the manufacturer of felbamate, Carter-Wallace, Inc., for the immediate withdrawal of patients from treatment with felbamine. Expand
An Analytic Study of Epileptic Falls
L'on insiste sur la très grande complexité de mécanismes physiopathologiques des chutes (ou drop attacks) de nature épileptique des chute ainsi définies comme une perte complète de la possibilité de maintenir la posture debout ou même assise, survenant dans une limite de temps d'une seconde ou moins. Expand